Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Ivosidenib is a potent inhibitor of mutant isocitrate dehydrogenase enzyme 1 (mIDH1), with activity against a variety of mutant IDH1 enzymes (IC50 range = 5-19 nM). Reduces intracellular 2-HG (Cat. No. 6122) by 96% at 0.5 μM. Increases sensitivity of melanoma to Temozolomide (Cat. No. 2706) in vivo and inhibits wild-type IDH1 in low magnesium and low nutrient levels. Ivosidenib also inhibits growth of tumors in cell and animal models of pancreatic cancer and inhibits invasion and migration of chondrosarcoma cells in vitro.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 582.96. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.72 mL||8.58 mL||17.15 mL|
|5 mM||0.34 mL||1.72 mL||3.43 mL|
|10 mM||0.17 mL||0.86 mL||1.72 mL|
|50 mM||0.03 mL||0.17 mL||0.34 mL|
References are publications that support the biological activity of the product.
Popovici-Muller et al (2018) Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med.Chem.Lett. 9 300 PMID: 29670690
Zarei et al (2022) Wild-type IDH1 inhibition enhances chemotherapy response in melanoma. J.Exp.Clin.Cancer Res. 41 283 PMID: 36153582
If you know of a relevant reference for Ivosidenib, please let us know.
Keywords: Ivosidenib, Ivosidenib supplier, mutant, IDH1, isocitrate, dehydrogenase, potent, inhibitors, inhibits, melanoma, pancreatic, cancer, invasion, migration, Isocitrate, 1, (IDH1), 7761, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Ivosidenib. Do you know of a great paper that uses Ivosidenib from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Ivosidenib and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.